Back
Edge
StocktwitsEarnings
Official STOCKTWITS Representative
symbol logo$MDGL Q4 '24 Earnings Results & Recap Madrigal Pharmaceuticals' Q4'24 results showed EPS of -$2.71 (beating expectations of -$3.84), and revenue of $103.32M (beating expectations of $100.51M). The company projects robust year-over-year net sales growth in 2025, with the launch of Resdipra continuing to show strength and a significant opportunity in the F4C patient population.
5

Since Post

Full Details

Advertisement|Remove ads.